Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oric Pharmaceuticals, Inc. (ORIC)
|
Add to portfolio |
|
|
|
| Price: |
$15.82
| | Metrics |
| OS: |
54.5
|
M
| |
-35
|
% ROE
|
| Market cap: |
$863
|
M
| |
-52
|
% ROIC
|
|
Net cash:
|
$274
|
M
| |
$5.02
|
per share
|
|
EV:
|
$589
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($93.8)
|
M
| |
|
|
| EPS |
($2.07)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 61.7 | 0.0 | 56.9 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | 8.5% | | | | | |
| Cost of goods sold | 0.0 | 61.7 | 0.0 | 78.9 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | -22.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 0.0% | | -38.7% | | | |
| Selling, general and administrative | 91.8 | | 78.9 | | 74.2 | 28.6 | |
| Research and development | 61.7 | | 56.9 | | 35.9 | 22.8 | 19.0 |
| General and administrative | | 25.1 | | 22.0 | | | 3.3 |
| EBIT | -84.1 | -86.8 | -78.7 | -78.9 | -49.0 | -27.2 | -22.4 |
| EBIT margin | | -140.7% | | -138.7% | | | |
| Pre-tax income | -89.1 | -89.1 | -78.7 | -78.7 | -73.7 | -26.9 | -21.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -89.1 | -89.1 | -78.7 | -78.7 | -73.7 | -26.9 | -21.4 |
| Net margin | | -144.5% | | -138.4% | | | |
| |
| Diluted EPS | ($2.25) | ($2.25) | ($2.07) | ($2.07) | ($3.36) | ($14.15) | ($12.32) |
| Shares outstanding (diluted) | 39.7 | 39.7 | 38.0 | 38.0 | 21.9 | 1.9 | 1.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|